Insider · CIK 0001694903
Richard E Uihlein
Files at GALT (GALECTIN THERAPEUTICS INC). First filing -, latest -.
In brief
Richard E Uihlein files SEC Form 4 as director and 10% owner at GALT (GALECTIN THERAPEUTICS INC). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Richard E Uihlein has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stockindirect: Richard E. Uihlein Stock Trust | +31,825,235 | $3.00 | $95M | 42,162,911 | Aug 4, 2026 |
| Jul 31, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Common Stockindirect: Richard E. Uihlein Stock Trust | +2,550,932 | $4.05 | $10M | 44,713,843 | Aug 4, 2026 |
| Jul 31, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Line of Credit Convertible Notesderivativeindirect: Richard E. Uihlein Stock Trust | - | $95,475,705.00 | - | 0 | Aug 4, 2026 |
| Jul 31, 2026 | GALT GALECTIN THERAPEUTICS INC | MOption exercise Line of Credit Convertible Notesderivativeindirect: Richard E. Uihlein Stock Trust | - | $10,331,275.00 | - | 0 | Aug 4, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Common Stock | +13,158 | $3.04 | $40k | 10,332,676 | Jan 21, 2026 |
| Jan 16, 2026 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 21, 2026 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Common Stock | +32,520 | $1.23 | $40k | 10,301,271 | Jan 27, 2025 |
| Jan 23, 2025 | GALT GALECTIN THERAPEUTICS INC | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 27, 2025 |
Questions about Richard E Uihlein
Answered from the filings on this page, as of the latest one.
Is Richard E Uihlein buying or selling?
Richard E Uihlein has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Richard E Uihlein's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Richard E Uihlein has 0.
Where does Richard E Uihlein file Form 4?
Richard E Uihlein has filed Form 4 at GALT (GALECTIN THERAPEUTICS INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.